Mohs surgery is not always necessary. It is the most precise method for removing skin cancer, but many skin cancers can be treated effectively with simpler, less expensive options. Whether you need Mohs depends on where the tumor is, how aggressive it looks under a microscope, whether it has come back after previous treatment, and your own priorities around scarring and cosmetic outcome.
When Mohs Surgery Is Strongly Recommended
Mohs surgery offers the highest cure rates available for skin cancer: 99% for primary basal cell carcinoma (BCC) and 94% for recurrent BCC over five years. Those numbers make it the gold standard, but they matter most in specific situations where the stakes are highest.
Tumors on the face, especially the nose, eyelids, ears, and lips, are the clearest case for Mohs. These areas have limited tissue to spare, and removing too much skin creates functional problems or visible scarring. Mohs allows the surgeon to examine 100% of the tumor’s margins during the procedure, removing cancer layer by layer and checking each one under a microscope before taking more. For infiltrative BCC, this approach spares about 46% of healthy tissue compared to standard excision, which takes wider margins as a safety buffer.
Aggressive tumor subtypes also push the decision toward Mohs. Infiltrative, sclerosing, morpheaform, and micronodular basal cell carcinomas spread beneath the skin in irregular patterns that are hard to predict visually. Standard excision uses predetermined margins and sends tissue to a lab afterward, meaning the surgeon won’t know for days whether they got everything. Mohs eliminates that uncertainty in real time.
Recurrent tumors, those that have come back after a previous treatment, are another strong indication. Scar tissue from the first procedure makes it harder to distinguish cancer from normal skin, and recurrent cancers tend to have irregular borders. Randomized trials have shown Mohs is significantly more effective than standard surgery for recurrent BCC, with five-year recurrence rates roughly half those of conventional excision.
When Simpler Treatments Work Well
For low-risk skin cancers on the trunk and extremities, standard excision or even less invasive options perform well enough that Mohs adds cost without a meaningful improvement in outcomes. In one large study comparing the three main approaches, the five-year recurrence rate was 2.1% for Mohs, 3.5% for standard excision, and 4.9% for electrodesiccation and curettage (a technique where the tumor is scraped away and the base is cauterized). When researchers matched patients by tumor characteristics, the difference between Mohs and standard excision was not statistically significant.
Electrodesiccation and curettage is the most common treatment for skin cancers on the trunk and limbs, used for roughly 69% of tumors in those locations in one registry. It’s faster, cheaper, and done in a single office visit. The tradeoff is a slightly higher recurrence rate and a less refined scar, but on areas usually covered by clothing, that tradeoff is reasonable for many people.
Topical treatments can also work for superficial basal cell carcinoma, the least aggressive type. A prescription cream applied at home over six weeks cleared 84% of superficial BCCs at three years, compared to 98% with surgical excision. That gap is real, and it means topical treatment is not equivalent to surgery. But for patients with multiple small, low-risk lesions, or those who want to avoid a procedure entirely, it remains a useful option depending on the tumor’s size and location.
The Cost and Practical Tradeoffs
Mohs surgery costs more than standard excision. One retrospective analysis found the average cost of Mohs with reconstruction was $3,534, compared to $2,644 for standard excision with pathology. The difference was statistically significant. Mohs also requires a specially trained surgeon and can take several hours, since each layer must be processed and examined before the next is removed. You’ll typically stay in the office the entire time, waiting between stages.
Standard excision, by contrast, is a single cut-and-close procedure that takes 20 to 40 minutes. The tissue goes to an outside lab, and you’ll get results in a few days. If margins come back positive (meaning cancer cells were found at the edge of the removed tissue), you may need a second procedure. That possibility is one reason some patients and surgeons prefer Mohs for borderline cases: it confirms clear margins before you leave the office.
How to Think About Your Situation
Four factors drive the decision. Location is the most important. A small BCC on your back is a very different situation from one on the tip of your nose. The face, genitals, hands, and feet all have strong cases for Mohs because tissue conservation matters and recurrence in those areas carries higher consequences.
Tumor type is next. If your biopsy report mentions infiltrative, morpheaform, sclerosing, or micronodular growth patterns, those subtypes spread unpredictably under the skin and benefit most from the margin-by-margin approach Mohs provides. A superficial or nodular BCC without aggressive features is far less likely to need it.
History matters too. A first-time, small, well-defined cancer on a low-risk body area is the easiest case for standard excision or curettage. A cancer that has already recurred, or one that was previously incompletely removed, shifts the calculation toward Mohs. The same is true for cancers showing perineural invasion, where tumor cells have started growing along nerve pathways.
Finally, your own priorities play a role. If minimizing the scar is important to you, Mohs conserves significantly more tissue. If cost or time in the office matters more, and your tumor is low-risk, a simpler approach may give you a nearly identical outcome with less hassle. The appropriate use criteria published jointly by several dermatology organizations weigh all of these factors together: tumor type, body location, lesion size, and pathology findings. There is no single answer that applies to every skin cancer.